55.21

5.58% 2.92

After Hours: 55.21

Rhythm Pharmaceuticals Inc (RYTM)

Overview News Price History Option Chain Financials Discussions Forecast

Rhythm Pharmaceuticals Inc stock is traded at $55.21, with a volume of 685.47K. It is up +5.58% in the last 24 hours and down -4.81% over the past month. Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Previous Close:

$52.29

Open:

$52.25

24h Volume:

685.47K

Relative Volume:

1.40

Market Cap:

$3.49B

Revenue:

$112.53M

Net Income/Loss:

$-258.91M

P/E Ratio:

-12.75

EPS:

-4.33

Net Cash Flow:

$-124.42M

1W Performance:

+7.58%

1M Performance:

-4.81%

6M Performance:

+1.21%

1Y Performance:

+41.13%

1-Day Range:

$52.15

$55.87

1-Week Range:

$50.13

$55.87

52-Week Range:

$35.17

$68.58

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name

Rhythm Pharmaceuticals Inc

Sector

Healthcare (1167)

Industry

Biotechnology (670)

Phone

857-264-4280

Address

222 BERKELEY STREET, BOSTON, MA

Employee

283

Twitter

@rhythmpharma

Next Earnings Date

2024-11-05

Latest SEC Filings

RYTM's Discussions on Twitter

Compare RYTM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RYTM Rhythm Pharmaceuticals Inc	55.21	3.49B	112.53M	-258.91M	-124.42M	-4.33
VRTX Vertex Pharmaceuticals Inc	512.52	131.61B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	672.36	73.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	619.97	37.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	253.44	32.81B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	266.26	28.62B	3.81B	-644.79M	-669.77M	-6.24

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-05-25	Resumed	Stifel	Buy
Jan-02-25	Initiated	Jefferies	Buy
Dec-20-24	Initiated	Oppenheimer	Outperform
Oct-21-24	Initiated	Guggenheim	Buy
Sep-18-24	Initiated	H.C. Wainwright	Buy
Sep-17-24	Initiated	JMP Securities	Mkt Outperform
May-08-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy
Jan-18-23	Resumed	Canaccord Genuity	Buy
Aug-08-22	Upgrade	Goldman	Neutral → Buy
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-22	Reiterated	Needham	Buy
Mar-02-22	Resumed	Stifel	Buy
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-14-21	Resumed	Goldman	Neutral
Aug-04-21	Downgrade	BofA Securities	Neutral → Underperform
Aug-04-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Nov-30-20	Downgrade	BofA Securities	Buy → Neutral
Jan-08-20	Initiated	Goldman	Sell
Jul-12-19	Upgrade	Stifel	Hold → Buy
Jul-08-19	Initiated	Canaccord Genuity	Buy
Mar-13-19	Initiated	Ladenburg Thalmann	Buy
Sep-07-18	Resumed	Morgan Stanley	Overweight
Jun-25-18	Reiterated	Needham	Buy
Jun-15-18	Reiterated	Needham	Buy
Oct-30-17	Initiated	BofA/Merrill	Buy
Oct-30-17	Initiated	Needham	Buy

View All

Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News

Mar 19, 2025

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted To Setmelanotide For Treatment Of Hypothalamic Obesity In Japan - Marketscreener.com

Mar 19, 2025

Rhythm Pharmaceuticals receives orphan drug status in Japan - Investing.com

Mar 19, 2025

Rhythm Pharmaceuticals Receives Orphan-Drug Designation in Japan for Obesity Treatment - MarketWatch

Mar 19, 2025

Rhythm Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire

Mar 19, 2025

Breakthrough for Rare Obesity: Rhythm's Drug Wins Special Status in Japan - StockTitan

Mar 19, 2025

Charles Schwab Investment Management Inc. Has $24.65 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Mar 19, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $66.00 Price Target at Needham & Company LLC - Defense World

Mar 19, 2025

Mar 18, 2025

Rhythm Pharmaceuticals EVP sells shares worth $3.86 million - Investing.com

Mar 18, 2025

Needham raises Rhythm Pharma stock target to $66, maintains buy By Investing.com - Investing.com UK

Mar 18, 2025

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Launch Research Collaboration on Fatigue in Craniopharyngioma Patients - Nasdaq

Mar 18, 2025

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration - GlobeNewswire

Mar 18, 2025

Major Breakthrough: Rhythm Pharma's New Research Tackles Devastating Fatigue in Brain Tumor Patients - StockTitan

Mar 18, 2025

Mar 15, 2025

Bank of New York Mellon Corp Sells 680 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Mar 15, 2025

Mar 14, 2025

Insider Sell Alert: EVP, Head of North America Jennifer Lee Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus.com

Mar 14, 2025

Mar 12, 2025

How To Trade (RYTM) - Stock Traders Daily

Mar 12, 2025

SBI Securities Co. Ltd. Invests $37,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Mar 12, 2025

Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target By Investing.com - Investing.com Canada

Mar 12, 2025

Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target - Investing.com India

Mar 12, 2025

Mar 10, 2025

Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World

Mar 10, 2025

Mar 09, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Overweight Rating from Morgan Stanley - Defense World

Mar 09, 2025

Mar 07, 2025

Assessing Rhythm Pharmaceuticals: Insights From 10 Financial Analysts - Benzinga

Mar 07, 2025

Promising Outlook for Rhythm Pharmaceuticals: Buy Rating Backed by Positive Phase 3 Study Expectations and Market Potential - TipRanks

Mar 07, 2025

Stifel Nicolaus Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World

Mar 07, 2025

Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $68.27 - Defense World

Mar 07, 2025

HC Wainwright Brokers Raise Earnings Estimates for RYTM - Defense World

Mar 07, 2025

Citizens JMP maintains Rhythm Pharma Outperform, $81 target By Investing.com - Investing.com South Africa

Mar 07, 2025

Mar 06, 2025

Citizens JMP maintains Rhythm Pharma Outperform, $81 target - Investing.com India

Mar 06, 2025

Principal Financial Group Inc. Purchases 4,298 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Mar 06, 2025

Brokers Issue Forecasts for RYTM FY2026 Earnings - Defense World

Mar 06, 2025

Promising Market Potential for Rhythm Pharmaceuticals’ Setmelanotide in Treating Hypothalamic Obesity - TipRanks

Mar 06, 2025

Mar 05, 2025

Stifel raises Rhythm Pharmaceuticals stock to Buy with $78 target By Investing.com - Investing.com Canada

Mar 05, 2025

US High Growth Tech Stocks to Watch in March 2025 - Yahoo Finance

Mar 05, 2025

Mar 04, 2025